Potential 1st-in-class Drug Shows Disease-Modifying Impact in AD
NEW YORK (Reuters Health) – A potential first-in-class anti-OX40 fully human monoclonal antibody has shown promise for treatment of moderate-to-severe
Read moreNEW YORK (Reuters Health) – A potential first-in-class anti-OX40 fully human monoclonal antibody has shown promise for treatment of moderate-to-severe
Read moreBEIJING (Reuters) – Chinese researchers are testing the mixing of COVID-19 vaccine doses developed by CanSino Biologics and a unit
Read moreNEW YORK (Reuters Health) – Dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) receptor alpha, should be considered in patients with
Read more